<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/15/3311996/0/en/isolved-Introduces-New-Strategic-Marketplace-Partners-at-Connect-2026-Extending-People-Cloud-Capabilities-for-Employers-and-Employees.html">isolved Introduces New Strategic Marketplace Partners at Connect 2026, Extending People Cloud™ Capabilities for Employers and Employees</a>
    </div>

      <div class="me-0 me-md-5">
        LAS VEGAS, June 15, 2026 (GLOBE NEWSWIRE) -- Connect For Partners – isolved, a provider of human capital management (HCM) solutions that help organizations recruit, retain and elevate their workforce, today announced new additions to its Strategic Marketplace — a curated ecosystem of best-in-class technology partners, each selected for the specific, meaningful value they bring to isolved client...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/15/3311865/0/en/paychex-recognized-as-a-top-worktech-company-by-time.html">Paychex Recognized as a Top WorkTech Company by TIME</a>
    </div>

      <div class="me-0 me-md-5">
        Paychex named a leading HCM provider to TIME&#39;s America&#39;s Top WorkTech Companies 2026 List List identifies the most impactful and financially strong companies that have established themselves as leaders in shaping how people and organizations work ROCHESTER, N.Y., June 15, 2026 (GLOBE NEWSWIRE) -- Paychex, Inc. (Nasdaq: PAYX), an industry-leading human capital management (HCM) company, today ann...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/12/3310859/0/en/HUTCHMED-Highlights-Sovleplenib-ESLIM-02-Phase-III-Data-in-Warm-Antibody-Autoimmune-Hemolytic-Anemia-Presented-at-EHA-2026-Congress.html">HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress</a>
    </div>

      <div class="me-0 me-md-5">
        — Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile — —The ESLIM-02 study underscores sovleplenib&#39;s potential to address critical unmet needs in a treatment landscape currently devoid of approved targeted therapies  — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 12, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/22/3299860/0/en/HUTCHMED-Highlights-Clinical-Data-to-be-Presented-at-the-2026-ASCO-Annual-Meeting.html">HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting</a>
    </div>

      <div class="me-0 me-md-5">
        HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, USA.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/21/3299110/0/en/HUTCHMED-and-Innovent-Jointly-Announce-NMPA-Approval-for-ELUNATE-Fruquintinib-in-Combination-with-TYVYT-Sintilimab-Injection-for-the-Treatment-of-Patients-with-Locally-Advanced-or-.html">HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma</a>
    </div>

      <div class="me-0 me-md-5">
        Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/20/3298636/0/en/Award-winning-HR-Software-Vendor-HiBob-Named-an-ISG-2026-Vendor-of-Excellence-for-Human-Capital-Management-HCM-Suites.html">Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Suites</a>
    </div>

      <div class="me-0 me-md-5">
        HiBob recognized as an ISG Vendor of Excellence for its comprehensive Human Capital Management Suite, demonstrating platform growth and market leadership HiBob recognized as an ISG Vendor of Excellence for its comprehensive Human Capital Management Suite, demonstrating platform growth and market leadership
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/18/3296760/0/en/Award-winning-HR-Software-Vendor-HiBob-Named-an-ISG-2026-Vendor-of-Excellence-for-Human-Capital-Management-HCM-Platforms.html">Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Platforms</a>
    </div>

      <div class="me-0 me-md-5">
        HiBob recognized as an ISG Vendor of Excellence for its innovative HCM Platform, highlighting its ability to unify and streamline global HR operations HiBob recognized as an ISG Vendor of Excellence for its innovative HCM Platform, highlighting its ability to unify and streamline global HR operations
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035">Hutchison China MediTech Limited Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/13/3294351/0/en/Chengdu-Origen-and-Vanotech-Announce-KHN921-Investigational-New-Drug-application-clearance-by-the-US-FDA-for-the-treatment-of-hypertrophic-cardiomyopathy-HCM-associated-with-MYBPC3.html">Chengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations</a>
    </div>

      <div class="me-0 me-md-5">
        Investigational New Drug application for KHN921 received “study may proceed” from the US FDA. KHN921 is a potential &quot;first-in-class&quot; cardiovascular AAV gene therapy being developed for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations Investigational New Drug application for KHN921 received “study may proceed” from the US FDA. KHN921 is a potential &quot;first-in-cl...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Hutchison-China-MediTech-Limited-Sponsored-ADR-US44842L1035/load_more?page=5">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>